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The challenge of non-communicable diseases 
(NCDs) continues to grow worldwide, increasing 
from 43% to 54% the global burden of disease 
between 1990 and 2016 (1). In 2018, NCDs 
accounted for 71% of total deaths globally, with 
81% of those deaths caused by four disease types – 
cardiovascular diseases, diabetes, cancers and 
chronic respiratory diseases (2). By 2025, the World 
Health Organization estimates, 85% of NCD 
annual deaths will occur in low- and middle-income 
countries (3).
The costs of treating NCDs have become 
enormous in all countries. For cardiovascular 
diseases alone, in the European Union, healthcare 
costs totalled €110 billion in 2015 (4). Adult (>20 
years) cases of diabetes worldwide have risen, from 
~171 million to 463 million people between 2000 
and 2019, accounting for 10% of healthcare 
expenditure (5,6). Moreover, given that this 
economic burden is likely to be especially heavy for 
disadvantaged and marginalised people and 
communities than in groups with higher 
socioeconomic status across all countries (7), NCDs 
are now a key driver of rising health inequities (8). 
Finally, as the COVID-19 pandemic shows, high 
rates of NCDs put millions of people at higher risk 
of other threats to health.
Given the substantial and rising costs, as Buse 
et al. note, ‘we cannot treat our way out of the NCD 
epidemic (9)’. Instead, more effective prevention 
strategies focused on reducing the risk factors 
associated with these diseases are urgently needed 
(10). A risk factor is ‘any attribute, characteristic or 
exposure of an individual that increases the likelihood 
of developing a disease or injury (11)’. However, 
public health action to prevent NCDs has to date 
primarily focused on metabolic (e.g. hypertension, 
hyperlipidaemia) and modifiable behavioural risk 
factors – tobacco use, harmful alcohol use, unhealthy 
diets and physical inactivity (2,12). As a result, as 
Horton describes, ‘progress has been inadequate and 
disappointingly slow. . ..An advocacy strategy based 
on four diseases and four risk factors seems 
increasingly out of touch. . ..Many political leaders 
believe that NCDs are just too big and too complex 
a challenge. And so they are paralysed. We need a 
different approach (13)’.
A profoundly different approach is the emerging 
concept of the commercial determinants of health 
(CDoH). It has long been recognised that NCD 
prevention strategies must address the ‘circumstances 
in which people are born, grow, live, work, and age, 
and the systems put in place to deal with illness (14)’. 
Since the late 20th century, it is arguable that the 
commercial (for-profit) sector has figured most 
heavily in shaping such social circumstances (15–18). 
West and Marteau define CDoH as ‘factors that 
influence health which stem from the profit motive 
(19)’. Similarly, Kickbusch et al. write that CDoH are 
‘strategies and approaches used by the private sector 
to promote products and choices that are detrimental 
to health (20)’. Buse et al. focus on ‘risks inherent 
from consumption of, or exposure to, commercial 
products – such as ultra-processed foods and 
beverages, tobacco and alcohol (21)’. These 
definitions contrast with recent WHO documents 
that consider nongovernmental organizations, 
philanthropic foundations, academic institutions 
and for-profit businesses all as ‘non-state actors’ and 
potential partners in NCD prevention and control 
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(22), a framing that masks potential conflicts of 
interest for commercial actors.
While this shift in attention to commercial factors 
is welcome, current definitions offer limited 
understanding of the complex pathways between 
CDoH and NCDs; do not take account of the 
variable and dynamic nature of CDoH over time 
and space; and do not consider the potential for 
positive and/or negative impacts on specific 
populations. As such, the concept of CDoH has not 
yet been operationalised to inform public health 
action effectively (9,21). Indeed, mainstream public 
health approaches remain focused on metabolic and 
behavioural risk factors such as screening for 
hypertension, healthy eating, smoking cessation and 
improved food-labelling strategies (23). However, 
interventions aimed at metabolic and behavioural 
risk factors, without taking account of ‘the inter-
relationships of social structure, context and agency 
in their impact on health and well being (24)’, have 
limited impact. The CDoH concept potentially 
integrates metabolic, behavioural and structural risk 
factors but, to do so, clearer definition beyond a 
focus on specific health-harming products and 
industries, along with analytical tools to measure CDoH 
as a composite of risk factors, are urgently needed.
Understanding the CDoH as a composite of risk 
factors, and how these risk factors interact with 
each other, is critical to the development of effective 
public health interventions to prevent and control 
NCDs worldwide. First, this approach shifts the 
dominant emphasis in research and policy on clinical 
management and behavioural change, which are 
costly and limited in effect, to prevention based on 
both societal- and individual-level change. Second, a 
composite CDoH approach bridges research and 
policy silos dividing different disease areas, 
population groups and types of interventions. 
Instead, these holistic approaches can amplify 
change through integrated strategies for NCD 
prevention. Finally, measuring the CDoH as a 
composite of risk factors allows clearer identification 
of relative vulnerabilities by specific populations 
over time and place, and across other variables (e.g. 
age, gender, socioeconomic status). This could 
provide a powerful dataset to develop targeted 
interventions and resources to reduce such risks to 
health and health equity.
A practical interdisciplinary CDoH framework 
can also incorporate new insights from systems 
science, political economy and political science, 
creating new bodies of knowledge that can inform 
public health practice. Systems science can help to 
create more coherent and grounded understanding 
of how dynamic systems of power and governance 
shape the pathways through which CDoH influence 
health (25). Political economy can help to trace the 
impact of the rise in neoliberalism on the role of 
commercial actors while political science can help to 
identify the social actors who have the power to 
modify CDoH (26).
Overall, despite clear evidence of the alarming rise 
in NCDs globally, and high-level political 
commitment to address this leading public health 
challenge, the public health community (including 
health promotion professionals) has achieved only 
limited consensus on effective preventive action 
(13,27). The CDoH concept promises a more 
holistic, integrated and targeted approach.
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